Logo

Genmab and Pfizer Secure the EC’s Approval for Tivdak (Tisotumab Vedotin) for Recurrent or Metastatic Cervical Cancer

Share this
Genmab & Pfizer

Genmab and Pfizer Secure the EC’s Approval for Tivdak (Tisotumab Vedotin) for Recurrent or Metastatic Cervical Cancer

Shots:

  • The EC has approved Tivdak an ADC, as a monotx. for adults (n=502) with recurrent or metastatic cervical cancer with disease progression on or after systemic therapy
  • Approval was backed by P-III (innovaTV 301) global trial evaluating Tivdak vs CT alone (topotecan, vinorelbine, gemcitabine, irinotecan, or pemetrexed)
  • The trial met its 1EP of OS, showing a 30% reduction in death risk with vs CT. Median OS was 11.5mos. v. 9.5mos. CT. 2EPs of PFS & ORR were also met, with a 33% reduction in the risk of disease progression vs CT. Data from the innovaTV 204 P-II trial evaluating Tivdak as monotx. in previously treated recurrent or metastatic cervical cancer was included in the MAA

Ref: Businesswire | Image: Genmab & Pfizer

Related News:- Pfizer Reports Data from P-III (TALAPRO-2) Trial of Talzenna + Xtandi for Metastatic Castration Resistant Prostate Cancer (mCRPC)

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Dipanshu Dixit

A passionate content writer with expertise in delivering high-quality and engaging content, Dipanshu is a keen reader and a versatile writer. Dipanshu dedicatedly covers news ranging from biopharma, life sciences, biotech, and MedTech to diagnostics and animal health companies, FDA, EMA, and biosimilar approvals. He can be contacted at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions